May 1, 2024 As part of Lupus Awareness Month, May 1 has been declared “Lupus Call to Action Day” by the National Minority Health Association (NMHA) and members of the lupus community. Kicking off at NYU Langone Health in New York City, the high-profile platform is designed to drive awareness and enact change to improve […] READ MORE
EAST RUTHERFORD, NEW JERSEY. May 1, 2024. Today, nearly 1,500 supporters plan to help tackle lupus at MetLife Stadium for the Lupus Research Alliance (LRA) 2024 New Jersey Walk with Us to Cure Lupus. Together, the passionate group of people with lupus and their friends and family expect to raise nearly $500,000 for lupus research […] READ MORE
Dear Friends, Lupus Awareness Month officially starts today, and with so many advancements, never has there been a time for more optimism. We are delighted to begin May following a productive first-anniversary meeting of the Lupus Accelerating Breakthroughs Consortium (Lupus ABC) where people with lupus partner with representatives from the FDA, industry, and researchers on […] READ MORE
April 15, 2024 An international task force recently published their recommendations for physical activity and exercise in people with systemic lupus erythematosus (SLE). While the benefit of physical activity in lupus is already recognized, no recommendations had been previously established. Published in the peer-reviewed journal Rheumatic & Musculoskeletal Diseases, this study outlines specific recommendations for […] READ MORE
BETHESDA, MD – [April 16] The Lupus Research Alliance (LRA), founder and administrator of the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), announced today at the Consortium’s first anniversary meeting an expanded partnership with the U.S. Food and Drug Administration (FDA) with the inclusion of the Center for Biologics Evaluation and Research (CBER). The addition of […] READ MORE
April 11, 2024 The Lupus Research Alliance (LRA) and its clinical research affiliate Lupus Therapeutics (LT) are pleased to announce the group of industry partners working together on the implementation of the Lupus Nexus. The Lupus Nexus, one of LRA’s most ambitious and groundbreaking endeavors, is a first-of-its-kind lupus registry, biorepository, and data exchange platform […] READ MORE
April 2, 2024 Determined to alleviate healthcare disparities for minorities, J. Christopher Reed, JD, urges our lupus community to use the power of National Minority Health Month to spotlight the issue this April. First diagnosed at 16, Christopher fought debilitating lupus symptoms to graduate college in eight years and then Tulane University Law School in […] READ MORE
March 28, 2024 Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, has announced an innovative expansion of the highly successful Patient Advocates for Lupus Studies (PALS) program with the introduction of a first-in-lupus “Trial Buddy” component made possible by a partnership with Bristol Myers Squibb. The Trial Buddy addition provides extra support […] READ MORE
March 23, 2024 The Lupus Research Alliance (LRA) mourns the loss of Richard K. DeScherer, the LRA’s Co-Founder and Co-Chair of the Board of Directors and Director Emeritus of Bloomberg L.P. The LRA extends our deepest condolences to his wife Jennie DeScherer along with their children — Kate DeSantis, Christopher DeScherer and his wife Amanda […] READ MORE
March 24, 2024 Congress and passed and President Biden signed the 2024 spending bills, which include priorities that you, our advocates requested last March. The Defense Appropriations bill includes $10 million for the Lupus Research Program within the Department of Defense. And the Agriculture-FDA bill includes a provision expressing support for FDA’s engagement with industry […] READ MORE
March 20, 2024 Lupus is a complex autoimmune disease affecting millions worldwide with a staggering gender imbalance — about 9 of 10 people with lupus are women. Underlying biological, hormonal, or environmental factors likely contribute to why lupus affects females more often. Understanding why women are at greater risk for lupus could unlock novel treatments […] READ MORE
NEW YORK, N.Y. — [March 14, 2024]: Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announced a collaboration with Artiva Biotherapeutics, Inc. on a Phase 1 trial of the company novel NK cell-based therapy AlloNK® (also known as AB-101), in combination with anti-CD20 antibodies, for patients with active lupus nephritis – inflammation […] READ MORE
